Atorvastatin glucuronidation is minimally and nonselectively inhibited by the fibrates gemfibrozil, fenofibrate, and fenofibric acid

被引:45
作者
Goosen, Theunis C.
Bauman, Jonathan N.
Davis, John A.
Yu, Chongwoo
Hurst, Susan I.
Williams, J. Andrew
Loi, Cho-Ming
机构
[1] Dept Pharmakokinetics Dynam & Metab, Pfizer Global Res & Dev, Ann Arbor, MI 48105 USA
[2] Amgen Inc, Seattle, WA USA
关键词
D O I
10.1124/dmd.107.015230
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Gemfibrozil coadministration generally results in plasma statin area under the curve (AUC) increases, ranging from moderate (2-to 3-fold) with simvastatin, lovastatin, and pravastatin to most significant with cerivastatin (5.6-fold). Inhibition of statin glucuronidation has been postulated as a potential mechanism of interaction (Drug Metab Dispos 30:1280-1287, 2002). This study was conducted to determine the in vitro inhibitory potential of fibrates toward atorvastatin glucuronidation. [H-3] Atorvastatin, atorvastatin, and atorvastatin lactone were incubated with human liver microsomes or human recombinant UDP-glucuronosyltransferases (UGTs) and characterized using liquid chromatography (LC)/tandem mass spectrometry and LC/UV/beta-radioactivity monitor/mass spectrometry. [ 3H] Atorvastatin yields a minor ether glucuronide (G1) and a major acyl glucuronide (G2) with subsequent pH-dependent lactonization of G2 to yield atorvastatin lactone. Atorvastatin lactonization best fit substrate inhibition kinetics (K-m = 12 mu M, V-max = 74 pmol/min/mg, K-i = 75 mu M). Atorvastatin lactone yields a single ether glucuronide (G3). G3 formation best fit Michaelis-Menten kinetics (K-m = 2.6 mu M, V-max = 10.6 pmol/min/mg). Six UGT enzymes contribute to atorvastatin glucuronidation with G2 and G3 formation catalyzed by UGTs 1A1, 1A3, 1A4, 1A8, and 2B7, whereas G1 formation was catalyzed by UGTs 1A3, 1A4, and 1A9. Gemfibrozil, fenofibrate, and fenofibric acid inhibited atorvastatin lactonization with IC50 values of 346, 320, and 291 mu M, respectively. Based on unbound fibrate concentrations at the inlet to the liver, these data predict a small increase in atorvastatin AUC (similar to 1.2-fold) after gemfibrozil coadministration and no interaction with fenofibrate. This result is consistent with recent clinical reports indicating minimal atorvastatin AUC increases (similar to 1.2-to 1.4-fold) with gemfibrozil.
引用
收藏
页码:1315 / 1324
页数:10
相关论文
共 40 条
[11]  
Jacob MME, 2000, J NEW MAT ELECTR SYS, V3, P3
[12]   Quantitative prediction of in vivo drug-drug interactions from in vitro data based on physiological pharmacokinetics:: Use of maximum unbound concentration of inhibitor at the inlet to the liver [J].
Kanamitsu, S ;
Ito, K ;
Sugiyama, Y .
PHARMACEUTICAL RESEARCH, 2000, 17 (03) :336-343
[13]   Effect of itraconazole on the pharmacokinetics of atorvastatin [J].
Kantola, T ;
Kivistö, KT ;
Neuvonen, PJ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 64 (01) :58-65
[14]   THE INTERCONVERSION KINETICS, EQUILIBRIUM, AND SOLUBILITIES OF THE LACTONE AND HYDROXYACID FORMS OF THE HMG-COA REDUCTASE INHIBITOR, CI-981 [J].
KEARNEY, AS ;
CRAWFORD, LF ;
MEHTA, SC ;
RADEBAUGH, GW .
PHARMACEUTICAL RESEARCH, 1993, 10 (10) :1461-1465
[15]   Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance [J].
Kyrklund, C ;
Backman, JT ;
Neuvonen, M ;
Neuvonen, PJ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (06) :538-544
[16]   Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate [J].
Kyrklund, C ;
Backman, JT ;
Kivistö, KT ;
Neuvonen, M ;
Laitila, J ;
Neuvonen, PJ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (05) :340-345
[17]   Effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers [J].
Lau, Y. Y. ;
Huang, Y. ;
Frassetto, L. ;
Benet, L. Z. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 (02) :194-204
[18]   Statin safety: A systematic review [J].
Law, M ;
Rudnicka, AR .
AMERICAN JOURNAL OF CARDIOLOGY, 2006, 97 (8A) :52C-60C
[19]  
Le Couteur D. G., 1996, P AUSTR SOC CLIN EXP, V3, P153
[20]   Clinical pharmacokinetics of atorvastatin [J].
Lennernäs, H .
CLINICAL PHARMACOKINETICS, 2003, 42 (13) :1141-1160